Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SCTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| STX-1150 | Elevated LDL-C and High Cholesterol | Phase 1 · NCT07428473 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SCTX holds $174.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $11.3M/quarter from operations, an estimated runway of 46.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Based on our current operating plan, we believe that 22 Table of Contents our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into the first half of 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SCTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Behzad Aghazadeh Director, 10% owner · +14,725 options |
Insider | 3,088,888 | 16.31% | 2026-07-24 |
| AH Bio Fund II, L.P. 10% owner |
Insider | 3,082,725 | 16.28% | 2026-07-27 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 1,802,178 | 9.52% | 2026-07-27 |
| ORBIMED ADVISORS LLC Director |
Insider | 1,348,825 | 7.12% | 2026-07-27 |
| Carl L Gordon Director · +14,725 options Includes shares also reported by ORBIMED ADVISORS LLC, counted once |
Insider | 1,348,825 | 7.12% | 2026-07-23 |
| LILLY & Co ELI 10% owner |
Insider | 1,054,828 | 5.57% | 2026-07-23 |
| Jennifer A Doudna 10% owner |
Insider | 603,547 | 3.19% | 2026-07-27 |
| Brett Staahl 10% owner · +43,525 options |
Insider | 524,336 | 2.77% | 2026-07-23 |
| Benjamin L. Oakes President, CEO, Director · +707,352 options |
Insider | 506,602 | 2.68% | 2026-07-23 |
| Svetlana Lucas Chief Business Officer · +228,399 options |
Insider | 30,695 | 0.16% | 2026-07-23 |
| David Parrot Chief Financial Officer · +227,761 options |
Insider | 2,666 | 0.01% | 2026-03-13 |
Share count 18,937,519 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SCTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →